Private equity firm KKR has acquired Medicover, the Sweden-based international healthcare and diagnostic services provider, in a deal valued at $1.5 billion. The transaction, which will take Medicover private, was confirmed by both parties, with the acquisition price representing a premium for shareholders of the Nasdaq Stockholm-listed company.
Medicover, founded in 1995 and headquartered in Sweden, operates across 19 countries with a workforce exceeding 48,000 employees. Its largest markets include Poland, Germany, Romania, India, and Ukraine. The company’s operations are split into two core divisions: Healthcare Services, which covers outpatient clinics, hospitals, specialist care, fertility treatment, dental and optician services, as well as wellbeing offerings such as sports packages; and Diagnostic Services, which provides a broad range of clinical laboratory tests spanning routine to advanced pathology areas.
For KKR, the acquisition aligns with its focus on investing in essential services with long-term growth potential. The healthcare sector in Central and Eastern Europe, where Medicover has a strong footprint, has shown consistent demand for private medical services, driven by rising incomes and an aging population. By taking Medicover private, KKR can support the company’s expansion plans without the short-term reporting pressures of public markets, potentially accelerating investments in new clinics, diagnostic capacity, and digital health solutions.
The deal is expected to provide Medicover with greater financial flexibility to pursue organic growth and selective acquisitions in existing and adjacent markets. KKR’s operational expertise in scaling healthcare businesses is likely to complement Medicover’s established network and brand reputation. The transaction is subject to regulatory approvals and is anticipated to close in the coming months, after which Medicover’s shares will be delisted from Nasdaq Stockholm.
Post-completion, the combined focus will be on strengthening Medicover’s position as a regional leader in integrated healthcare and diagnostics, while maintaining service quality across its diverse geographies. The company’s management team is expected to remain in place, ensuring continuity for patients and employees during the transition.